The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
HOME > ACADEMIA
ACADEMIA
- Avigan Interim Analysis Not Intended to Determine Efficacy, Research Sponsor Says on Reports
May 21, 2020
- Infection Society's Updated COVID-19 Guide Includes Information on Veklury
May 15, 2020
- Investigator Calls for Early Listing of Zolgensma in Japan
May 12, 2020
- Univ. of Tokyo Starts Testing Avigan Plus Futhan for COVID-19
May 11, 2020
- 5-Year Cancer Survival Rates Up 2 Points to 64.1%: NCC
April 17, 2020
- Gunma Univ. Hospital Plans Clinical Research Covering Hydroxychloroquine
April 13, 2020
- BCG’s Efficacy in COVID-19 Not Yet Confirmed: Japan Vaccine Society
April 6, 2020
- Researchers Unlock SAL Inhibitory Mechanism of Obesity Med Orlistat; Potential Treatment for MRSA/Atopic Dermatitis
March 30, 2020
- Otsuka, NCC Develop Comprehensive Genomic Profiling Assay for Blood Cancer
March 27, 2020
- Japan Plans Alvesco Clinical Trial for Coronavirus
March 24, 2020
- Japan to Join NIH-Sponsored COVID-19 Trial for Gilead’s Remdesivir
March 24, 2020
- Pancreatitis Drug Nafamostat Potentially Effective for COVID-19: Researchers
March 19, 2020
- COVID-19 Patients in Japan Improved on Plaquenil
March 11, 2020
- Camostat Potential Treatment for COVID-19: German Study
March 11, 2020
- Alvesco Inhibits RNA Replications: NIID
March 9, 2020
- With Sudden Spotlight on Alvesco for COVID-19, Teijin Being Flooded with Inquiries
March 6, 2020
- Asthma Drug Alvesco Possibly Effective for COVID-19
March 4, 2020
- Kyoto Univ., NTT Launch New Company to Analyze, Provide RWD; Label Expansions Eyed for Cancer Drugs
February 5, 2020
- TMDU Research Team Calls for New Hypothesis on Cause of AD; Could Lead to Development of Gene Therapy
January 28, 2020
- Impact of Oligonucleotides - 3: Advances in Modified Oligo Technologies Pave Way for Innovative Drug Arrivals
January 20, 2020
ページ
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…